# In vivo optoacoustic imaging of endothelin receptor expression and treatment response in the hypoxic tumor microenvironment

**Authors:** Carsten Höltke, Moushami Mallik, Miriam Stölting, Emily Hoffmann, Christiane Geyer, Raghu Erapaneedi, Friedemann Kiefer, Anne Helfen

PMC · DOI: 10.1007/s00259-025-07494-7 · European Journal of Nuclear Medicine and Molecular Imaging · 2025-08-13

## TL;DR

This study explores using optoacoustic imaging to track a specific receptor in tumors under low oxygen conditions and how it responds to treatment.

## Contribution

The study introduces a novel use of ETAR-targeted optoacoustic imaging to assess hypoxic tumor environments and treatment response.

## Key findings

- ETAR expression in hypoxic tumors was successfully visualized using optoacoustic imaging.
- Therapies reduced ETAR signal and increased tumor oxygenation, indicating treatment response.
- Combining ETAR imaging with hemoglobin readouts reveals reoxygenation and immune modulation.

## Abstract

A hypoxic tumor microenvironment promotes cancer progression, with endothelin-A receptor (ETAR) signaling playing a key role in tumor neoangiogenesis and macrophage infiltration. We hypothesize that multispectral optoacoustic tomography (MSOT) using an ETAR-specific probe could provide improved insights into the hypoxic characteristics of the tumor microenvironment (TME), either alone or in combination with endogenous markers, and that alterations in ETAR expression may correlate with increased tumor oxygenation serving as an early indicator of response to anti-angiogenic or immune-modulating therapy.

A fluorescent ETAR probe was applied for in vivo MSOT evaluation of ETAR expression in hypoxic murine breast cancer. Optoacoustic signal intensity (SI) of deoxygenated and oxygenated hemoglobin served as additive intrinsic readouts. Furthermore, therapeutic interventions utilizing Bevacizumab, Clodronate and Sorafenib were evaluated with regard to effects on ETAR expression and hemoglobin oxygen saturation. Imaging results were validated ex vivo via immunohistochemistry.

Exposure of 4T1 murine breast cancer cells to hypoxic conditions led to upregulation of ETAR in vitro. In vivo, tumor growth correlated with increased ETAR probe signal intensity in 4T1 tumors. All therapeutic interventions significantly reduced ETAR SI following treatment. Anti-angiogenic therapies also increased tumor oxygen saturation, indicating therapy-induced re-oxygenation.

ETAR expression in hypoxic tumor regions can be visualized non-invasively by MSOT using an exogenously administered targeted probe. Combining ETAR-targeted imaging with intrinsic hemoglobin readouts enables assessment of reoxygenation and immune cell modulation in response to therapy. Thus, ETAR has potential as an in vivo imaging biomarker for early therapy response in experimental breast cancer studies.

The online version contains supplementary material available at 10.1007/s00259-025-07494-7.

## Linked entities

- **Proteins:** EDNRA (endothelin receptor type A)
- **Chemicals:** Clodronate (PubChem CID 25419), Sorafenib (PubChem CID 216239)
- **Diseases:** breast cancer (MONDO:0004989)
- **Species:** Mus musculus (taxon 10090)

## Full-text entities

- **Genes:** Ednra (endothelin receptor type A) [NCBI Gene 13617] {aka AEA001, ET-AR, ETa, Gpcr10, Mhdaaea1}
- **Diseases:** breast cancer (MESH:D001943), cancer (MESH:D009369), hypoxic (MESH:D002534)
- **Chemicals:** oxygen (MESH:D010100), Clodronate (MESH:D004002), Bevacizumab (MESH:D000068258), Sorafenib (MESH:D000077157)
- **Species:** Mus musculus (house mouse, species) [taxon 10090]
- **Cell lines:** 4T1 — Mus musculus (Mouse), Malignant neoplasms of the mouse mammary gland, Cancer cell line (CVCL_0125)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12830490/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12830490/full.md

## References

1 references — full list in the complete paper: https://tomesphere.com/paper/PMC12830490/full.md

---
Source: https://tomesphere.com/paper/PMC12830490